Current Medical Research and Opinion
Volume 38, 2022 - Issue 9
Oncology
Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L
Karen L. Reckampa Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USACorrespondence[email protected]
https://orcid.org/0000-0002-9213-0325
https://orcid.org/0000-0002-9213-0325, Huamao M. Linb Global Evidence and Outcome, Takeda Development Center Americas Inc., Lexington, MA, USAhttps://orcid.org/0000-0002-8399-8966
https://orcid.org/0000-0002-8399-8966, Holly Cranmerc Global Market Access, Takeda Pharmaceuticals International Co., London, UKhttps://orcid.org/0000-0002-9067-3422
https://orcid.org/0000-0002-9067-3422, , , Stephen Kaye Department of Statistics, Model Outcomes Ltd., Cheshire, UKhttps://orcid.org/0000-0002-2104-7460
https://orcid.org/0000-0002-2104-7460, , , Sanjay Popath Lung Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, UKhttps://orcid.org/0000-0003-2087-4963
https://orcid.org/0000-0003-2087-4963 & show all